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ReviewIn monoaminergic neurons, the vesicular transporters
and the plasma membrane transporters operate in a relay.
Amphetamine and its congeners target this relay to
elicit their actions: most amphetamines are substrates,
which pervert the relay to elicit efflux of monoamines into
the synaptic cleft. However, some amphetamines act as
transporter inhibitors. Both compound classes elicit pro-
found psychostimulant effects, which render them liable
to recreational abuse. Currently, a surge of new psycho-
active substances occurs on a global scale. Chemists
bypass drug bans by ingenuous structural variations,
resulting in a rich pharmacology. A credible transport
model must account for their distinct mode of action
and link this to subtle differences in activity and unde-
sired, potentially deleterious effects.
Amphetamines – a diverse class of compounds
The amphetamines are a diverse class of chemical com-
pounds. They comprise synthetic compounds and natu-
rally occurring alkaloids such as ephedrine and cathinone
(Box 1), which are synthesized in the plant species Ephe-
dra and Catha, respectively. Extracts from these plants
have been used for their remedial and psychostimulant
effects for millenia (for an excellent historical overview
see [1]). Laza˘r Edeleanu synthesized the eponymous com-
pound amphetamine in Berlin in 1887 (Box 1); many
derivatives were produced within the next two decades
[1]. The availability of pure compounds allowed their
pharmacological characterization, which was initiated
by Sir Henry Dale [2]. Biel and Bopp [3] chemically
defined an amphetamine as containing: (i) an unsubsti-
tuted phenyl ring, (ii) a two-carbon side chain between the
phenyl ring and nitrogen, (iii) an a-methyl group, and (iv)
a primary amino group (Box 1). Many compounds meet
these criteria. In addition, the targets (i.e., the mono-
amine transporters) apparently interpret the rules in a
flexible manner: for instance, methamphetamine, ephed-
rine, and methylphenidate violate the primary-amine0165-6147/
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mine transporter; addiction.rule (Box 1). Hence, this large group of compounds is
difficult to define on chemical grounds. An operational
definition based on the pharmacology (‘amphetamine-like
action’) falls short of accounting for the complex mode of
action: in fact, there is a continuum ranging from amphet-
amine-triggered release to methylphenidate-induced
blockage of uptake. A clear-cut definition would facilitate
imposing legal restrictions on marketing activities. The
difficulties arising from a chemistry-based definition are
also exemplified by cathinones: the naturally occurring
cathinone is a ketone. It serves as a scaffold for numerous
substitutions: methylation produces meth(yl)cathinone,
which allows regulations restricting the sales of cathinone
to be bypassed. However, cathinone derivatives are not
only used illicitly: they include the antidepressant drug
bupropion and the anorectic agent diethylpropion. Syn-
thetic analogs of methcathinone have recently become
popular as ‘designer drugs’ or ‘legal highs’ on the illicit
drug market [4]. Often, they are referred to as ‘bath
salts’, ‘plant food’, or ‘research chemicals’ to facilitate
their distribution and to obviate prosecution. Popular
methcathinone derivatives are 4-methylmethcathinone
(mephedrone, Box 1) and 3,4-methylenedioxymethcathi-
none (methylone). More recently, 3,4-methylenedioxypyr-
rovalerone (MDPV, Box 1) has reached the market; it is
an example of a very potent, psychoactive synthetic cath-
inone and illustrates the problem of a laissez-faire ap-
proach to recreational drug use: MDPV exerts stimulant-
like effects at low doses, but life-threatening side effects
are seen at high doses or upon chronic use [5]. Accordingly,
the authorities have banned amphetamines including
the first-generation synthetic cathinones such as mephe-
drone, methylone, and MDPV in the USA and the EU.
Ignorance is blatant with respect to new psychoactive
substances (NPS) which flood the drug market at present
(Box 2). Chemical substitutions may render a given drug
compatible with current legislation, but they may also
introduce dramatic changes in the activity of the com-
pound and in its mode of action. Widespread consumption
of NPS may be associated with health risks such as
neurodegeneration. These are linked – at least in part
– to the mode of action. Accordingly, it is of relevance to
elucidate the different modes of action of amphetamine,
its congeners, and in particular of stimulant NPS. TheTrends in Pharmacological Sciences, January 2015, Vol. 36, No. 1 41
Box 1. Structural differences between amphetamines
The chemical definition by Biel and Bopp [3] posits the presence of
(i) an unsubstituted phenyl ring, (ii) a two-carbon side chain between
the phenyl ring and a nitrogen, (iii) an a-methyl group, and (iv) a
primary amino group in a compound to qualify as an amphetamine
(Figure I). Panel (A) illustrates this rule. Panel (B) shows the trace
amine phenethylamine which is produced in higher organisms,
while panels (C,D) show the structures of the plant alkaloids
ephedrine and cathinone. Panels (E–I) show the structural diversity
in amphetamines, which either conform to (E) or violate the chemical
definition of Biel and Bopp rule (F–I). Accordingly, amphetamines
are a diverse group of compounds that target the transporters for
monoamine neurotransmitters, but do not engage their cognate
receptors [75]. Moreover, the individual structural differences
between the different amphetamines highlight the specificity
between monoamine transporters, for example the SERT over DAT
selectivity of pCA and fenfluramine [1,76], or the DAT-preference of
D-amphetamine [75]. However, amphetamines also bind to non-
monoamine transporter targets such as adrenergic receptors [1] or
trace amine receptors [77]. These receptors form complexes with
transporters [78]; trace amine-associated receptor (TAR) agonists
(including amphetamines) inhibit uptake [79,80]. These observations
point to a possible role of TARs in the treatment of amphetamine
addiction. The compound structures are reproduced from the
PubChem database.
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Figure I. Chemical structures of amphetamines.
Review Trends in Pharmacological Sciences January 2015, Vol. 36, No. 1main targets of amphetamines (and presumably of many
stimulant NPS) are the neurotransmitter:sodium sym-
porters (NSS) for the monoamines dopamine (DAT/solute
carrier protein SLC6A3), serotonin (SERT/SLC6A4), and
noradrenaline/norepinephrine (NET/SLC6A2). Ampheta-
mines are exogenous substrates of and generate a
current through these transporters [6]. The action of42amphetamine has been studied for more than 100 years
[2]. Nevertheless, there are still many open questions: (i)
how do these compounds differ from physiological sub-
strates to act as efficient releasers? (ii) What is the role of
protein kinases in triggering efflux? (iii) Does the oligo-
meric arrangement of monoamine transporters affect
the action of amphetamine? (iv) Why does amphetamine
Box 2. New psychoactive substances: scrutinizing their mode of action
The term ‘new psychoactive substances’ (NPS) refers to a wide variety
of compounds which elicit psychotomimetic effects. These drugs
include stimulants that are congeners of amphetamine or synthetic
cathinones. Their street market names ‘designer drugs’, ‘bath salts’,
‘plant food’, or ‘research chemicals’ imply an innocuous recreational
consumption. However, NPS is not restricted to compounds that act like
amphetamine: also cannabimimetics, sedative-hypnotics, and also
hallucinogens such as 2-CB (2,5-dimethoxy-4-bromophenethylamine),
a partial agonist at 5HT2A-receptors, and related receptor ligands are
also classified as NPS [81]. NPS are not harmless: 4-methyl-N-
methylcathinone (mephedrone) and 3,4-methylenedioxypyrrovalerone
(MDPV) do not only exert psychostimulant effects – they cause
deleterious side effects at higher doses [82]. Therefore, the marketing
and the consumption of these drugs have been prohibited in many
countries. However, this ban predictably drives an evolutionary arms
race: ingenuous chemists create novel compounds and thus circum-
vent the legislation. Currently, there is a surge of NPS on the drug
market, including some ‘second-generation’ cathinones and conge-
ners. As with all novel active compounds – whether developed for the
legal or the illicit drug market – it is worthwhile to elucidate the principal
mechanism of action. This claim is supported by the following line of
arguments. In the case of NPS, the candidate targets are monoamine
transporters. It is necessary to explore whether the new substance acts
as a releasing or an inhibiting agent. Both types of drugs increase the
synaptic concentrations of monoamines in central nervous tissue, but
they differ significantly in their mode of action: substrates induce
transporter-mediated sodium currents (i.e., depolarization [1]) and
initiate transporter-mediated monoamine efflux (i.e., reverse transport
or release), whereas blockers do not. Importantly, amphetamine-
associated depolarization puts neurons at risk: in fact, the use of
fenfluramines has been associated not only with neuronal depletion of
5-HT [76], but also with pulmonary hypertension and valvular heart
disease [83]. The latter arises from the long-term effect of serotonin on
the pulmonary vasculature.
Two simple diagnostic assays can be employed to assess the nature
of the compound under scrutiny: (i) electrophysiological recording of
transport-associated currents and/or (ii) examination of the initiation
of reverse transport comparing control conditions and intracellular
high-sodium conditions. The first experiment employs either cells or
Xenopus laevis oocytes, which heterologously express monoamine
transporters, and compares the concentration–response curve of the
NPS to that of reference compounds. The second experiment relies
on the elevation of intracellular sodium concentrations by blockage of
the Na+/K+-ATPase, or by applying the Na+/H+-ionophore monensin
which selectively exchanges Na+ for H+ [14]: under these conditions a
bona fide releaser potentiates release, while a blocker is inactive (for
an example see the characterization of MDPV in [84].
The illicit drug market provides a powerful incentive to circumvent
the legal ban via chemical modifications. NPS are actually predicted
to increase in numbers [85]. Furthermore, street drugs are increas-
ingly adulterated with a plethora of different compounds, some of
which may lead to most severe side effects [86]. This justifies the
effort to not only analyze the composition of street drugs but also the
mode of action of these combinations [86,87].
Review Trends in Pharmacological Sciences January 2015, Vol. 36, No. 1elicit a blocking (paradoxical) action on disease-
associated mutants of, for example, the dopamine trans-
porter/SLC6A3? (v) Does the lipid composition of the
plasma membrane affect the action of amphetamine?
In this review we address these issues and argue that
their resolution is important to understanding the differ-
ences in the actions of individual compounds.
The principle targets of amphetamines: monoamine
transporters
In monoaminergic neurons, retrieval of neurotransmit-
ters into the synaptic vesicles is accomplished by a relay
that is made up of several components (Figure 1):
(i) vesicles are tethered to the plasmalemmal monoamine
transporter (DAT, SERT, or NET). The resulting spatial
proximity promotes efficient (re)filling of the docked vesi-
cle at the reuptake site [7]. (ii) The turnover number of
the reserpine-sensitive, proton-driven vesicular mono-
amine transporter VMAT2 (400 min1) [8] is higher than
that of the plasmalemmal transporters (120–180 min1)
[9,10]. This creates a sink and limits diffusion of mono-
amines within the cytosol of the presynaptic bouton.
(iii) This is further enhanced by the action of mitochon-
drial monoamine oxidases (MAO-A and B) and catechol
O-methyltransferase (COMT) [11] which degrade cytosol-
ic monoamines. Amphetamines interact with several
targets within this relay; in other words, they are exoge-
nous substrates of the plasmalemmal transporters (DAT,
SERT, NET), and of the vesicular transporters VMAT1
and VMAT2, and inhibit MAO. The concerted action of
amphetamines on these three targets is the core tenet of
the ‘weak base hypothesis’ [12,13]: amphetamines enter
monoaminergic terminals via DAT, SERT, or NET and
subsequently accumulate in the synaptic vesicles by theaction of VMATs. Therein, by their physicochemical na-
ture, they dissipate the proton gradient and preclude
inward transport of monoamines. The resulting elevation
in cytosolic monoamine neurotransmitters is further
aggravated by MAO inhibition. Thus, they rise to concen-
trations that allow occupation of the internal substrate
binding site [14] and their subsequent outward transport
by plasmalemmal transporters. Amphetamines also
bind to the trace amine receptors TAR1, a Gs/Gq-coupled
receptor, and to LGC (ligand-gated channel)-55, an
amine-gated chloride channel related to the pentameric
ligand-gated channels (e.g., GABAA or glycine receptors)
and which was originally identified in C. elegans [15]. Fi-
nally, it is also likely there are also additional unidenti-
fied targets, for example a cytosolic target that accounts
for the ability of amphetamine to downregulate surface
levels of the glutamate transporter EAAT3 [16]. Several
arguments suggest that the monoamine transporters are
the principal site of action, which must be addressed by
amphetamines to elicit their biological responses, in par-
ticular their psychostimulant effects. While blockage of
VMAT allows the accumulation of cytosolic dopamine, it
fails to induce dopamine release in DAT-deficient neurons
[17]. Furthermore, TAR1 is not activated by all psychoac-
tive amphetamines ( p-chloroamphetamine, for instance,
is inactive); stimulation of TAR1 actually reduces dopa-
mine release and thus decreases sensitivity to amphet-
amine [18,19]. The preferred ligands for the amine-gated
chloride channel LGC-55 are tyramine and phenylethyl-
amine; amphetamine engages the channel only at high
concentrations (EC50 around 150 mM) [20]. In addition,
the internalizing action on EAAT3 explains long-term
changes in neuronal excitability but cannot account for
the immediate action of amphetamines [16].43
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Figure 1. Schematic of the transport cycle. A kinetic scheme of substrate (S)
interaction with either the outward- (o) or inward- (i) facing transporter (T) and with
cotransported substrates. Substrates can be either physiological substrates such
as monoamines or amphetamines; co-substrates can be sodium (Na+) or chloride
(Cl). There are several additional reactions: in other words, sequential binding of
Na+ ions, chloride, and substrate to the outward-facing conformation, and the
corresponding release steps from the inward-facing conformation ([27] for a more
detailed model). These have been omitted for the sake of clarity. The transporter
switches from the outward- to the inward-facing conformation via an occluded
state (occ). In the serotonin transporter (SERT) the return through the occluded
empty state is contingent on binding of K+ (symbolized by K+ in brackets). The
conducting state (Cond) is achieved via an inward-facing conformation [27]. In the
presence of amphetamine, amply supplied internal substrate and elevated internal
sodium, the transporter releases substrate by running backwards through the
cycle (reaction pathway indicated by red arrows). Burst-like dopamine (DA)
effluxing events have been recorded by Kahlig and colleagues [47], but their
relation to the transport cycle is unclear (indicated by the dashed arrow on the left-
hand side).
Review Trends in Pharmacological Sciences January 2015, Vol. 36, No. 1The psychostimulant action of amphetamines relies on
reverse transport
Transport by NSS is by definition coupled to the downhill
movement of ions. Accordingly, NSS rely on Na+/K+-
ATPase which generates gradients for sodium (outsi-
de>>inside) and potassium (inside>>outside). In most
cells, chloride moves passively along its electrochemical
gradient driven by the membrane potential (outside>>in-
>inside). It is generally accepted that sodium and chloride
serve as transported co-substrates for NSS [21]. In the
transport cycle, two sodium ions and one chloride ion and
the substrate are sequentially loaded into the outward-
facing conformation of the transporter, are transiently
locked into an occluded state transport and, upon opening
of an inner gate, are finally released into the cytosol. The
ability of the monoamine transporters to concentrate sub-
strate substantially more than 10-fold by inward trans-
port suggests that two Na+ ions are cotransported. It is
worth pointing out that there is no formal proof for co-
transport of Cl and of the second Na+ ion. Thus, it is not
known in which state the transporter completes the cycle
(returning in the empty apo-state or in a Na+- and/or44Cl-bound state). It is clear though that SERT differs from
its close relatives by relying on the potassium gradient for
the return step [22]. Given that monoamines are thought
to be transported as charged species (i.e., with their amine
nitrogen protonated) [23], it is possible to deduce the
tentative net charge movement across the membrane
during the transport cycle based on the stoichiometries:
for SERT, where flux measurements suggest only a single
Na+ ion moves with the substrate, the balance predicts no
charge movement, while for DAT and NET positive charge
moves into the cell [22]. Surprisingly, all three monoamine
transporters generate transport-associated currents. The
transport cycle is based on the alternating access model,
which was originally conceived as a Gedanken experiment
[24]. It is the most plausible description of substrate
translocation; in fact, the predicted intermediates (e.g.,
outward-facing, occluded substrate-bound; inward-facing,
occluded empty stage) have been visualized in the crystal
structures of several bacterial transporters, including the
homolog for mammalian neurotransmitter transporters,
the leucine transporter LeuTAa [25]. A detailed kinetic
analysis indicates several additional intermediate states
in SERT [26,27]. It is gratifying to note that nine different
conformations have already been identified in crystals of
the bacterial betaine transporter BetP [28,29]. Although
BetP is unrelated to SLC6 transporters, it uses the same
fold of pseudosymmetric inverted repeats for the translo-
cation process [30]. There is one major set of observations,
however, that have been difficult to reconcile with the
alternative access model. These are the transport-associ-
ated currents seen in all monoamine transporters
[31,32]. Their magnitude suggests that charge is moved
in considerable excess to the translocated substrate, indi-
cating that the stoichiometries outlined above cannot
account for the current. Accordingly, it was proposed that
transporters function in a channel mode, in which the
outer and inner gates open simultaneously, and substrate
and ions permeate in single-file mode [33,34]; this may be
true for SERT of Drosophila melanogaster [35]. However,
detailed kinetic analysis shows that the conducting state
of human SERT is reached via an inward-facing confor-
mation, which allows influx of sodium ions; the magnitude
of the uncoupled conductance is limited because the prob-
ability that the transporter assumes this particular con-
formation is low [27]. It therefore appears unlikely that
the channel mode is the preferred transport mode of
mammalian transporters.
The principal mechanism by which amphetamine elicits
its biological responses, in particular the psychostimulant
effects, is accounted for by its ability to induce efflux of
monoamines by reverse transport. This effect is large in
magnitude, it does not require any neuronal activity, and
has hence been termed non-exocytotic release. Before
dwelling on the mechanistic details, it is worth pointing
out that amphetamines are taken up by plasma-membrane
monoamine transporters as exogenous substrates [31]. Ac-
cordingly, they inhibit the physiological monoamine reup-
take in a competitive manner [36]. As a consequence of
both amphetamine-induced reverse transport and inhibi-
tion of reuptake, the synaptic monoamine concentration
increases, which in turn activates post- and presynaptic
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Figure 2. The molecular effects of amphetamines. Schematic illustration of the
effects of amphetamines (AMPH, light-green circles) on the reverse operation of
neurotransmitter:sodium symporters (NSS). NSS are present in the plasma
membrane either as monomers or oligomers [46]. They are physically linked to
the vesicles, and this allows their efficient refilling with monoamines (MA, yellow
circles) [7]. The oligomer-based counter-transport model [50] is shown on the left
side of the figure and illustrates that the effect of amphetamine relies, at least in
part, on an intact oligomer. Amphetamines target the vesicular monoamine
transporter (VMAT) and lead to either inhibition and/or reversal of the transport
direction to increase the cytosolic concentration of MA, thereby enabling reverse
transport. Furthermore, amphetamines inhibit enzymes such as monoamine
oxidases A and B (MAO) and thereby prevent the degradation of MA.
Abbreviation: TAR1, trace amine receptor 1.
Review Trends in Pharmacological Sciences January 2015, Vol. 36, No. 1receptors [37]. The activation of postsynaptic receptors
propagates the signal and contributes to the biological
response. Stimulation of presynaptic autoreceptors
decreases the quantal release of monoamines upon excit-
atory inputs; this is further supported by the observed
depletion of vesicular monoamine storage by ampheta-
mines acting at the vesicular monoamine transporters
(see above).
How to account for the reverse transport mode
Amphetamines generate a current which exceeds the
stoichiometrically coupled ion movement that accompa-
nies the transport process: an uncoupled conductance
[31,32]. Hence, the exogenous substrate amphetamine will
compete with the endogenous substrates on the intracel-
lular side for binding to the transporter primary binding
site. In addition to the coupled conductance accompanying
the electrogenic NSS such as DAT and NET, the uncoupled
conductance, in particular in SERT, raises the intracellu-
lar sodium levels and increases the affinity of the trans-
porter for all substrates available for outward transport.
Therefore, any rise in intracellular sodium (e.g., by block-
ade of the Na+/K+-ATPase, or dissipation of the sodium
gradient by the sodium–proton ionophore monensin), trig-
gers efflux of endogenous substrates – a conjecture that has
been experimentally verified [14,38]. In addition, if trans-
membrane ion gradients are changed, reversal of transport
is initiated either upon lowering of extracellular sodium
[39] or raising extracellular potassium concentrations
[40]. Thus, there are two conceptually important types of
reverse transport: (i) the trigger is the binding to and
transport of releasers, and (ii) changes in the ion composi-
tion of the extra- or intracellular fluid. In either case, there
must be a releasable pool of substrate accessible on the
cytoplasmic side, which is kept low under physiological
conditions by the relay outlined above.
Several models have been proposed to account for the
reverse transport. Originally, the explanation focused on
the ‘alternating access hypothesis’ as a starting point.
Accordingly, the transporter was metaphorically proposed
to operate as a ‘revolving door’: the outward transport of
the physiological monoamine was initiated by the inward
transport of amphetamine. This model assumed that (i) the
trigger (and thus the driving force) was provided by the
binding and inward movement of the amphetamine mole-
cule, and (ii) forward and reverse transport were accom-
plished by the same transporter molecule. This was
inferred from the observed substrate and inhibitor selec-
tivity; for example, cocaine blocks substrate uptake and
amphetamine-induced substrate efflux [41]. This ‘revolv-
ing door’ model is also referred to as ‘facilitated exchange
diffusion model’ [42].
The conceptual problem with the revolving door meta-
phor is evident from an inspection of the transport cycle
(Figure 1): the physiological return step is the apo-version
of the transporter, in other words the empty transporter (in
the case of SERT, this state is thought to be the K+-loaded
version of the transporter, see above). Amphetamines can
per se drive the full transport cycle because they elicit
transport-associated currents, which are carried by the
empty inward facing conformation [27]. At present, it isunclear if the transporter can accommodate K+ and sub-
strate at the same time during its return step. Neverthe-
less, it is unclear if the K+ hypothesis holds true for SERT
alone or if it could even be extended to the other members
of the SLC6 family. Thus, simple ‘exchange diffusion’
requires the transporter to run in reverse, similarly to
an enzymatic back-reaction; in other words, it would mean
that the transporters move through the steps from the
outside to the inside and back (Figure 1). The revolving
door metaphor for the explanation of reverse transport is at
the very least misleading, because the transporter only
moves through a half-cycle: the revolving door is in fact
jammed. This interpretation is supported by the observa-
tion that high internal, physiological substrate levels pre-
clude the appearance of the channel mode [26]. In other
words, in the presence of high internal substrates, the
transporter is less likely to visit conformations in the
left-hand part of the scheme in Figure 1: it seesaws through
the right-hand part of the cycle. The semantics may be
ignored, but there are additional issues that must be
addressed.
First, if exchange diffusion was so readily achievable,
the monoamine transporters would be prone to futile
cycling when transporting their cognate substrates. It
may be argued that rapid removal by the vesicular45
Review Trends in Pharmacological Sciences January 2015, Vol. 36, No. 1monoamine transporters may prevent futile cycling, but
there is little evidence of futile cycling of cognate sub-
strates in the absence of vesicular transporters: it is not
seen in transfected cells which express monoamine trans-
porters. Amphetamines are prone to futile cycling because
they diffuse back through the membrane [26].
Second, it is questionable that the very same transport-
er moiety, which supports amphetamine influx, is the
moiety that acts as the outward carrier for cognate sub-
strate. SLC6 transporters form oligomers [43,44]. These
are formed in the endoplasmic reticulum (ER) but, at the
cell surface [45], the oligomers are kinetically trapped (i.e.,
they do not readily exchange [46]) (Figure 2). These oligo-
mers may account for amphetamine-induced release
spikes or bursts, which are detected by amperometry when
DAT-expressing cells are challenged with amphetamine
[47]. The burst-like release was originally attributed to a
channel mode which supported spikes of dopamine efflux
[47]. The assumption underlying this interpretation is to
posit an internal binding site for amphetamine which is not
recognized by the cognate substrate. Occupation of this site
by amphetamine is thought to promote long-lasting open
states, and this action has been metaphorically referred to
as the ‘molecular stent hypothesis’ [48]. There are many
arguments that question this model [26,49]. Suffice it to
say that it is also doubtful on chemical grounds that DAT
can form a continuous aqueous pore which is selective for
dopamine but does not allow the permeation of amphet-
amine. Thus, we propose that the burst-like release ofBox 3. C- and N-termini as regulatory hubs
Compared to bacterial SLC transporters, mammalian monoamine
transporters have extended C-and N-termini [25]. By contrast, the N-
and the C-termini of eukaryotic SLC6 transporters have more >60 and
>25 residues, respectively. The translocation process is accomplished
by the hydrophobic core (i.e., the 12 transmembrane helices). It is
therefore conceivable that eukaryotic transporters have evolved to
allow regulatory input (Figure I). This can be illustrated by considering
the fact that bacterial transporters are directly co-translationally
inserted into the target membrane, in other words the inner membrane.
By contrast, eukaryotic transporters are synthesized in the ER and they
must traffic through the secretory pathway to reach the cell surface.
Accordingly, the C-terminus contains several signals that are required
for anterograde trafficking, specifically the SEC24 binding site [88].
The coarse-grained modulation of neuronal excitability is accom-
plished by the activation of ion channels: propagation of axonal
action potentials is an all-or-none phenomenon. Transport processes
participate in fine-tuning neuronal activity. Hence, transport proteins
undergo extensive regulation by post-translational modifications (i.e.,
phosphorylation, ubiquitylation, and palmitoylation – as indicated in
Figure I and [21,64]). These modifications mostly occur at the N- and
C-termini – the sites that are accessible to intracellular kinases; in
addition, a few candidate sites have also been identified in
intracellular loops. Finally, the C-terminal domain supports regulatory
events that move the transporter either from the cell surface into the
cell interior (e.g., the FREKLAYAIA motif in the DAT [89]) or from the
ER to the plasma membrane (e.g., the interaction with the coat protein
COPII-dependent vesicular machinery [90]). In addition, the C-
terminus contains signals that allow retrograde trafficking, in other
words endocytosis (e.g., the FREKLAYA motif in the DAT). The N- and
C-termini also allow post-translational modifications, of which
phosphorylation has been the most extensively studied: several
phosphorylation sites have been identified in DAT and SERT, and
many have been confirmed by mass spectrometry. The kinases
involved include protein kinase B (Akt), protein kinase C (PKC), protein
kinase G (PKG), extracellular signal regulated kinase (ERK), casein
46dopamine reflects (more or less) synchronous outward
transport by higher-order oligomers. Because these are
less frequent than monomers and dimers (e.g., hexamers
are <10% [46]), spikes of release are detected at low
frequency over amperometric noise. It is also worth noting
that amphetamines can trigger release of GABA through a
concatemer of SERT and GAT1 [50]. There are additional
findings which support the conjecture that the oligomeric
nature of monoamine transporters is important for the
action of amphetamines ([51] for review). This may be
difficult to reconcile with the observation that amphet-
amine dissociates oligomers [52,53]. However, oligomer
formation was assessed by co-immunoprecipitation from
detergent extracts and by crosslinking. The amphetamine-
induced changes may reflect a conformational change and
a difference in lipid environment (see below).
Third, membrane lipids modify the transport activity of
SERT and DAT. This includes cholesterol, which promotes
inward transport [54,55]. In fact, cholesterol has been
visualized in the crystal structure of Drosophila DAT,
wedged in a groove formed by transmembrane helices
1a, 5, and 7 [56]. This helps to explain why cholesterol
promotes the outward-facing conformation of DAT
[54]. The second lipid known to affect monoamine trans-
porter is the phosphoinositide phosphatidylinositol-4,5-
bisphosphate (PIP2). PIP2 is a low-abundance constituent
of the inner leaflet, serves as a precursor of signaling
molecules (i.e., inositoltriphosphate, IP3; and diacylgly-
cerol, DAG), and is a signaling molecule in its own right:kinase II (CKII), Ca2+/calmodulin-dependent protein kinase IIa (aCaM-
KII), p38 MAP Kinase (MAPK; see selected overview in Figure I and
[64,91] for comprehensive review,). In many instances, however, the
effect of phosphorylation is poorly understood. This is illustrated by
considering the consequence of PKC-dependent phosphorylation:
activation of PKC (which can be triggered by amphetamines and
much less by endogenous substrates [51]) results in decreased
transport capacity for uptake of substrate [21]. This downregulation
can be linked to PKC-dependent ubiquitination of DAT and its
subsequent degradation [92]. Surprisingly, deletion or exchange of
the N-terminal phosphorylation sites in the DAT does not blunt PKC-
mediated downregulation [93]. Another possibility is that phosphor-
ylation triggers the interaction between monoamine transporters and
the SNARE (soluble NSF attachment protein receptor) protein
syntaxin 1, and this can have functional consequences (reviewed in
[1,75]). Last but not least, it must be stressed that the regulation taking
place in transfected cells may not be relevant in the physiological
context: while PKC-dependent downregulation of DAT (and of SERT)
has been consistently observed in transfected cells, there is still
debate about whether it occurs in primary neurons [94]. Importantly,
differences exist among the monoamine transporters in relation to
the role and extent of phosphorylation. Although the N- and C-termini
differ substantially, amphetamines can induce reverse transport in all
three transporters, and this is believed to be triggered by transporter
phosphorylation. However, as mentioned in Box 1, their selectivity
and potency to induce transporter-mediated efflux differ considerably
[83], which may be inferred from secondary effects such as binding to
associated proteins or interaction with membrane constituents: In
SERT and DAT the binding site for PIP2 is formed by non-contiguous
segments that include membrane-adjacent segments of the N- and C-
termini. The activity of SERT and DAT is also regulated by PIP2 (see
main text and [58,59]). Thus, binding of PIP2 allows regulatory input
by other signals: PIP2 is consumed by receptor-mediated activation of
PLC isoforms and is replenished by PI-4 kinase and to PIP2 by PIP-5
kinase, which are also subject to regulation.
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Figure I. The N- and C-termini of DAT and their regulatory inputs. The figure was obtained and modified with permission from James Foster and Roxanne Vaughan
[64]. The N- and the C-termini of eukaryotic SLC6 transporters have >60 and >25 residues, respectively, and allow regulatory input. For instance, the C-terminus
contains several signals (as indicated) that are required for anterograde and retrograde trafficking (e.g., the interaction with the COPII-dependent vesicular machinery
[88,90], and e.g., the FREKLAYAIA motif in the dopamine transporter DAT [89], respectively). Furthermore, transport proteins undergo extensive regulation by post-
translational modifications – phosphorylation, ubiquitylation, and palmitoylation (as indicated by serines undergoing phosphorylation marked ‘S’, ubiquitylation sites
marked ‘Ub’, and a palmitoylation site marked ‘Pal’). aCaMKII also directly attaches to the C-terminus of DAT and phosphorylates the N-terminus (indicated as CaMK).
Membrane-bound proteins that interact with DAT are the SNARE protein syntaxin 1A (in yellow, abbreviated Syn1A) and flotillin 1 (abbreviated as Flot1). The interaction
between the DAT-N-terminus and the membrane-bound phosphoinositides is depicted with the two-headed arrows in red and PIP2. Abbreviations: CaMKII, Ca
2+/
calmodulin-dependent protein kinase II; COPII, vesicle coat protein II; DAT, dopamine transporter; PIP2, phosphatidylinositol-4,5-bisphosphate; SLC, solute carrier
protein; SNARE, soluble NSF attachment protein receptor.
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teins, in particular of transporters (e.g., Na+/Ca2+-exchang-
er [57]) and ion channels (e.g., voltage-gated K+ and Ca2+
channels [34]). SERT and DAT are also regulated by PIP2
[58,59]. Manipulations that deplete PIP2 reduced amphet-
amine-induced currents through, and reverse transport by,
SERT without affecting inward transport or surface levels
[58]. These observations show that PIP2 can specifically
affect the conformational equilibrium in the transport
cycle. The very binding site of PIP2 in DAT appears to
affect the membrane trafficking of DAT [59]. Importantly,
the functional impact of the PIP2–DAT interaction is me-
diated by the N-terminus: abolishing binding of PIP2 to
DAT by introducing the appropriate mutations also spe-
cifically eliminated amphetamine-induced efflux [59]. Most
importantly, Drosophila melanogaster knock-in flies which
express this mutant (human) DAT rather than their en-
dogenous version are phenotypically normal unless chal-
lenged with amphetamine: basal locomotion (and circadian
rhythm) is identical to that of wild type flies but the
amphetamine-induced hyperactivity is greatly reduced[59]. This experiment formally proves that the interaction
of PIP2 with DAT is relevant to the action of amphetamine
in vivo. A further observation suggests that the membrane
lipid environment is important: DAT is targeted to lipid
microdomains (detergent-resistant membranes or ‘lipid
rafts’) by flotillin-1: depletion of flotillin-1 blunts amphet-
amine-induced substrate efflux in neurons [60] and am-
phetamine-induced hyperlocomotion in Drosophila
melanogaster [61]. It is also worth noting that there is
an obvious link to protein kinase-dependent regulation of
monoamine transporters (see also below): disruption of the
interaction with flotillin-1 also impairs the regulation of
DAT by protein kinase C (PKC) [60] and Ca2+/calmodulin-
dependent protein kinase II (CaMKII) [62]. Finally, the
interaction between DAT and flotillin is relevant to under-
standing attention deficit/hyperactivity disorder (ADHD):
DAT-R615C, a heterozygous mutation associated with
ADHD, fails to associate with flotillin but is constitutively
associated in a complex with CaMKII [63].
Fourth, there is ample evidence that the phosphoryla-
tion in DAT and also SERT contribute to the action of47
Box 4. Medically relevant amphetamine use and cognitive
enhancement
Amphetamine and substituted congeners have been in use as over-the-
counter and prescription medicines for a plethora of different diseases
[95]. However, as rapidly as amphetamines conquered the drug market,
critical voices were raised pointing out several caveats against such a
panacea: amphetamines were no longer freely available, their prescrip-
tion was strictly regulated and restricted to defined indications. At
present, only a few amphetamines are approved for medical use:
methylphenidate, D-amphetamine, and lisdexamphetamine. All three
medications are approved for the treatment of attention deficit
hyperactivity disorder (ADHD) and narcolepsy by the US FDA and the
corresponding agencies of other countries. Methylphenidate is a
reuptake inhibitor at DAT and NET, but not SERT; lisdexamphetamine
is a prodrug of dexamphetamine; the latter two drugs act as releasers at
DAT and NET, and to a lesser extent at SERT [96]. There is more clinical
evidence to support the use of methylphenidate [95]. In addition, these
drugs have been examined in several other disorders including affective
disorders, eating disorders, fatigue, multiple sclerosis, and, although
counter-intuitive, schizophrenia ([95] for comprehensive overview).
Amphetamines have also been suggested to be useful as cognitive
enhancers [97]. Admittedly, amphetamines can measurably increase
cognitive performance, a phenomenon that was noted some 80 years
ago [98]. Mankind has used the stimulatory effects of several different
naturally occurring compounds such as caffeine, nicotine, ibogaine,
cathinone, and ephedrine for thousands of years. Greely and colleagues
[97] advocated measures to make amphetamines available to reap the
benefits of cognitive enhancement. However, this plea must be
reconciled with the possible risks of addiction and other serious side
effects (e.g., neurodegeneration, pulmonary hypertension). Further-
more, the therapeutic window of amphetamines is small: although they
enhance the stringency of thought and the speed of decision-making,
prolonged intake of higher dose can lead to cognitive impairment [99],
and therapeutic doses can even lead to increased error rates during
episodic memory retrieval [100]. It cannot be ruled out that novel
psychostimulantsmayemerge that boosthuman cognitive performance
and carry a reduced risk of adverse events and addiction. However, the
current evidence suggests that this is unlikely in the near future.
Review Trends in Pharmacological Sciences January 2015, Vol. 36, No. 1amphetamines (reviewed in [64]): amphetamine-induced
efflux is blunted by elimination of the phosphorylation
sites in the N-terminus of DAT [41] or by inhibition of
either PKC or aCaMKII [50,65–69]. Most importantly,
there is formal proof that CaMKII interacts with DAT
[66–68] and modifies the amphetamine-induced dopamine
efflux in vivo in mice [69]. Furthermore, mice deficient in
aCaMKII have a reduced locomotor response to amphet-
amine; in addition, behavioral sensitization is also im-
paired [69]. Thus, aCaMKII not only supports acute
amphetamine-induced dopamine efflux but is also impor-
tant in shaping the chronic response to amphetamine. A
mechanistic explanation must take into account the inter-
play of candidate phosphorylation sites, the lipid environ-
ment, and the oligomeric arrangement (see above). The
most plausible explanation is to posit that (i) C- and N-
termini are in close vicinity (for which there is direct
evidence [70,71]) and (ii) are engaged and modified by
kinases at the cognate sites, which (iii) introduces negative
charges, and thus may alter the interaction of the trans-
porter with phospholipids, and (iv) the resulting conforma-
tional change is transmitted by the N-terminus, which acts
as a lever: restricting the mobility or truncation of the N-
terminus eliminates amphetamine-triggered efflux
[10]. DAT is palmitoylated at C580 in the proximal segment
of its C-terminus [72]. Palmitoylation counteracts the ac-
tion of PKC (i.e., to promote downregulation; Box 3). At the
very least, these observations provide circumstantial evi-
dence for a relation between phosphorylation and the lipid
environment of the membrane (palmitoylation affects the
association of protein with lipid rafts).
Concluding remarks
The transport cycle is governed by a series of conforma-
tional equilibria. Rate constants have been inferred from
electrophysiological measurements [27], but the thermo-
dynamics underlying the transition are not understood.
It is conceivable that the conformational equilibria in the
cycle may depend on the oligomeric state of the trans-
porter and the lipid environment and that it can be
shifted by regulatory modifications (phosphorylation,
palmitoylation) state and/or by mutations. A mechanistic
interpretation of the action of amphetamines must take
the transport cycle into account. We have argued that a
seesaw mode is the most plausible way to account for the
kinetics of reverse transport. This exchange diffusion
mode is facilitated by conformational switches, which
are brought about by the concerted action of the N-
terminus of the transporter and the lipid environment
in which the transporter is embedded. Thus, transporter
may function as a signal integrator and coincidence
detector. In the presence of elevated intracellular Na+,
the appropriate lipids, and an activated kinase, mono-
amine transporters may also function as a device to
allow physiological monoamine release [73]. Similarly,
mutations may shift monoamine transporters into this
release mode: a prominent example is DAT-A559V, which
was identified in individuals affected by ADHD [74]. Un-
der these conditions, amphetamines may predominantly
act as inhibitors, a conjecture which was verified for
DAT-A559V. At the very least, this hypothesis is worth48exploring because it may explain the paradoxical benefi-
cial actions of amphetamines in ADHD (Box 4).
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